Brief: Regen Biopharma Expands Vision For Phase 1 Clinical Trial Of Hemaxellerate
19/11/2024 22:19
Nov 19 (Reuters) - Regen BioPharma Inc RGBP.PK :
* REGEN BIOPHARMA, INC. EXPANDS VISION FOR PHASE 1 CLINICAL
TRIAL
OF HEMAXELLERATE™
Source text: ID:nGNXcdVz4v
Further company coverage: RGBP.PK
Recent news on Regen BioPharma
See all newsBrief: Regen Biopharma Prepares Response For FDA Regarding Its Orphan Drug Application For HemaXellerate
Brief: Regen Biopharma Expands Vision For Phase 1 Clinical Trial Of Hemaxellerate
Brief: Regen Biopharma, Inc. Receives First Phase Of Confirmatory Study
Brief: Regen Biopharma Files Provisional Patent On Car-T Cell Capable Of Attracting And Educating Naïve T Cells
Brief: Regen Biopharma addresses potential impact of recent Bristol Myers Squibb's $2.3 billion acquisition of IFM Therapeutics